Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27081312 | 1.00 | KIF11 (0.50) | KIF11KCNH2SLC6A2SLC6A4MEN1 | |
| SCHEMBL14168221 | 0.88 | KIF11 (0.53) | KIF11KCNH2TK1 | |
| SCHEMBL4917240 | 0.88 | KIF11 (0.53) | KIF11KCNH2TK1 | |
| SCHEMBL19522241 | 0.87 | SLC6A1 (0.44) | KIF11KCNH2MEN1KMT2ATK1 | |
| SCHEMBL15281845 | 0.87 | KIF11 (0.49) | KIF11KCNH2MEN1KMT2ATK1 | |
| SCHEMBL3490250 | 0.87 | KIF11 (0.49) | KIF11KCNH2MEN1KMT2ATK1 | |
| SCHEMBL8633174 | 0.86 | KIF11 (0.48) | KIF11KCNH2MEN1KMT2A | |
| SCHEMBL13160566 | 0.85 | KIF11 (0.52) | KIF11KCNH2TK1 | |
| SCHEMBL13388489 | 0.85 | KIF11 (0.50) | KIF11KCNH2 | |
| SCHEMBL21431103 | 0.84 | TK1 (0.46) | KIF11KCNH2MEN1KMT2ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. | 2024-06-27 | — | — | US | disclosed |
| CN-118006604-A | Covalent cross-linked hammerhead ribozyme and preparation method and application thereof | 兰州交通大学 | 2024-05-10 | — | — | CN | disclosed |
| EP-4313984-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | Genscript USA Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117222647-A | Universal linker reagents for DNA synthesis | 金斯瑞美国公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| WO-2022204102-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-3992291-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-2248820-B1 | Universal supports for oligonucleotide synthesis | GLEN RES CORP (US) | 2014-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | KIF11 4071/4885KCNH2 4855/4885SLC6A2 2365/4885 |
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | GALNT2, ST6GAL1, SLC17A5 | KIF11 2975/4885KCNH2 3564/4885SLC6A2 257/4885 |
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | RNGTT, DTYMK, UNG | KIF11 2536/4885KCNH2 3973/4885SLC6A2 2695/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | KIF11 4158/4885KCNH2 4853/4885SLC6A2 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.